Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 13/20 | 0.75 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.73 |
| ▸ | MAOB | P27338 | 2/20 | 0.73 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.73 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.73 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.73 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.73 |
| ▸ | MMP1 | P03956 | 2/20 | 0.63 |
| ▸ | MMP2 | P08253 | 2/20 | 0.63 |
| ▸ | MMP9 | P14780 | 2/20 | 0.63 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3211603 | 1.00 | BACE1 (0.75) | BACE1AKR1B1MAOBAKR1B10PTGS2 | |
| SCHEMBL16589019 | 0.93 | BACE1 (0.64) | BACE1AKR1B1MAOBAKR1B10PTGS2 | |
| SCHEMBL3219281 | 0.86 | BACE1 (1.00) | BACE1AKR1B1MAOBAKR1B10PTGS2 | |
| SCHEMBL3219293 | 0.86 | BACE1 (1.00) | BACE1AKR1B1MAOBAKR1B10PTGS2 | |
| Bisdemethoxycurcumin SCHEMBL2574140 | 0.86 | AKR1B1 (1.00) | BACE1AKR1B1MAOBAKR1B10PTGS2 | |
| Bisdemethoxycurcumin SCHEMBL428638 | 0.86 | AKR1B1 (1.00) | BACE1AKR1B1MAOBAKR1B10PTGS2 | |
| SCHEMBL3209234 | 0.85 | BACE1 (0.68) | BACE1AKR1B1MAOBAKR1B10PTGS2 | |
| SCHEMBL3209220 | 0.85 | BACE1 (0.68) | BACE1AKR1B1MAOBAKR1B10PTGS2 | |
| SCHEMBL3214146 | 0.84 | BACE1 (0.68) | BACE1AKR1B1MAOBAKR1B10PTGS2 | |
| SCHEMBL3222373 | 0.84 | TTR (0.77) | BACE1AKR1B1MAOBAKR1B10PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962674-B2 | Curcumin derivative | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-02-24 | — | — | US | disclosed |
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2123637-A1 | NOVEL CURCUMIN DERIVATIVE | Tokyo Institute of Technology (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | BACE1, APP, BACE2 | BACE1 1/4885AKR1B1 1096/4885MAOB 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.